

# eQcell Inc. Announces Appointment to Scientific Advisory Board

Press Release

Guelph, Ontario, Canada | October 17, 2025

**eQcell Inc.**, Canada's premier clinical-stage regenerative medicine company addressing conditions and diseases affecting sporting and domestic animals globally, is pleased to announce the appointment of Dr. Sowmya Viswanathan to its Scientific Advisory Board.

Dr. Viswanathan is a Scientist at the Osteoarthritis Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute and the Krembil Research Institute (University Health Network) and an Associate Professor at the Institute of Biomedical Engineering and Department of Medicine, University of Toronto. She is co-Director of the Schroeder Arthritis Advanced Therapeutic Centre.

Her research is focused on developing novel cellular and immunotherapies to target osteoarthritis (OA), including i) using proprietary enhanced mesenchymal stromal cells (MSCs), and ii) reprogramming monocytes/macrophages, using small molecules and gene edited iPSCs

"eQcell's continues to consolidate its industry-leading scientific team towards the discovery and development of advanced therapeutic solutions across the equine, canine, and feline health markets" explained eQcell's Founder and CEO, Dr. Thomas Koch.

## About eQcell Inc.

eQcell was founded within the Ontario Veterinary College/University of Guelph, Canada, the 6<sup>th</sup>-ranked veterinary university in the world. The research into stem cells at OVC has been supported by grants and expenditures approximating \$6 million over a 15-year period, and external funding from investors in eQcell, exceeding \$6 million since 2021, has provided the necessary capital to initiate clinical trials in Canada and the United States and establish its sources for GMP manufacturing. Trials in osteoarthritis are being conducted at Colorado State University College of Veterinary Medicine & Biomedical Sciences and Canada's premier veterinary hospital – The Ontario Veterinary College. eQcell became and remains the only company authorized by Canada's Veterinary Drugs Directorate to conduct clinical trials in equine osteoarthritis with MSCs.

eQcell has adopted One Health principles under which successful clinical data in the veterinary indication supports preclinical models for translation of its platform into treatments for humans. Osteoarthritis is a major cause of pain and disability in humans for which for which current treatments are ineffective, not fully effective, or palliative and that affect ~33 million US adults and over 500 million worldwide. The

translational nature of the veterinary data is reported to importantly reduce the failure rate in late-stage human trials that approximate 70% at Phase II and 50% at Phase III, reducing risks of capital loss, encouraging investment.

For further information on eQcell:

Dr. Thomas G Koch - CEO and CSO - [tkoch@eqcell.com](mailto:tkoch@eqcell.com)

